secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2026-06-09T20:05:26+00:00
Accession:  0001628280-26-041883
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shareholders approve all proposals; board adopts updated director compensation program
--------------------------------------------------------------------------------

- Three Class III directors elected: Patrick J. Heron, Neha Krishnamohan, Todd Franklin Watanabe.
- Ernst & Young ratified as independent auditor for fiscal year 2026.
- Non-binding advisory vote approved named executive officer compensation.
- Revised director comp: $50k base retainer, $350k initial option, annual $350k award (65% options, 35% RSUs).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000162828026041883/0001628280-26-041883-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000162828026041883/arqt-20260605.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-041883

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer